- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Lupin Limited — Updates, 10-08-2026: Press Release
10-08-2026 | 05:59 pm
10-08-2026 | 05:59 pm
Lupin secured U.S. FDA approval for Sodium Zirconium Cyclosilicate Oral Suspension, a drug for hyperkalemia. The reference product had estimated annual sales of USD 56.8 Cr, indicating a significant market opportunity.
No comments yet. Be the first to comment!